Anthropic’s Amodei to Meet Wiles With US Seeking Mythos Access

 

Anthropic PBC Chief Executive Officer Dario Amodei is scheduled to meet on Friday with White House Chief of Staff Susie Wiles, according to people familiar with the matter, as the Trump administration seeks wider US government access to the company’s powerful new Mythos artificial intelligence model.

The discussions could set the stage for major federal agencies to eventually start using Mythos. Gregory Barbaccia, federal chief information officer of the White House Office of Management and Budget, said in an email Tuesday that OMB is setting up protections that could allow their agencies to begin using the closely guarded AI tool.

https://www.bloomberg.com/news/articles/2026-04-17/anthropic-s-amodei-to-meet-wiles-with-us-seeking-mythos-access

Kura 44% response, 94% disease control for darlifarnib plus cabozantinib in clear cell renal cell carcinoma

 

Kura Oncology reports 44% response, 94% disease control for darlifarnib plus cabozantinib in cabozantinib-pretreated clear cell renal cell carcinoma

• Preliminary subset results are from the FIT-001 trial in cabozantinib-pretreated clear cell renal cell carcinoma.

https://finviz.com/quote.ashx?t=KURA&p=d

Immuron reports unaudited Q3 FY26 Travelan sales growth across Australia, Canada and the U.S.

 

• Australia Travelan sales rose 15% year-on-year in unaudited Q3 FY26.
• Canada Travelan sales increased 82% quarter-on-quarter in unaudited Q3 FY26.
• U.S. Travelan sales rose 1% on the prior corresponding period in unaudited Q3 FY26.

https://finviz.com/quote.ashx?t=IMRN&p=d

Polymarket Data Shows 54% Chance of U.S.-Iran Peace Deal

 On April 17, 2026, the likelihood of a U.S.-Iran peace agreement has surpassed 50% for the first time, with Polymarket indicating a 54% probability of a deal by April 30. This marks a significant increase of 32 percentage points recently. Iran has reopened the Strait of Hormuz for commercial shipping following a ceasefire between Israel and Lebanon. The trading activity has been vigorous, exceeding $12 million, reflecting strong investor interest and a belief in a potential diplomatic resolution despite past volatility in negotiations. 

https://www.gurufocus.com/news/8801090/polymarket-data-shows-54-chance-of-usiran-peace-deal

Trump Says Iran Is Removing Sea Mines From Strait of Hormuz

 

President Donald Trump said Iran is removing sea mines from the Strait of Hormuz, a step that could expand commercial shipping traffic through the vital waterway.

Trump posted on social media Friday that Tehran “has removed, or is removing” all mines from the strait “with the help of the U.S.A.” The president’s claim could not be immediately verified. The New York Times reported last week that Iran had been unable to locate every mine it laid, citing anonymous US officials.

https://www.bloomberg.com/news/articles/2026-04-17/trump-says-iran-is-removing-sea-mines-from-strait-of-hormuz

Yardeni: Market Optimism Amid Strong Earnings Growth

 On April 17, 2026, Edward Yardeni, president of Yardeni Research, expressed optimism for equity investors, highlighting a potential earnings-driven market surge supported by strong corporate performance and reduced geopolitical tensions. Notably, Microsoft Corp MSFT has been a standout performer in the technology sector, contributing significantly to a broader market rally.

https://www.gurufocus.com/news/8801036/microsoft-msft-drives-market-optimism-amid-strong-earnings-growth

Corvus Buy Rating from Goldman Sachs

 On April 17, 2026, Corvus Pharmaceuticals Inc CRVS experienced a notable increase in its stock price following a Buy rating initiated by Goldman Sachs, which set a price target of $40. Analyst Paul Choi highlighted the potential of the company's lead candidate, soquelitinib, which is being developed for atopic dermatitis and other autoimmune disorders. With shares up over 400% in the past year, Choi emphasized that the stock is currently undervalued, considering forthcoming catalysts over the next 12-18 months.

https://www.gurufocus.com/news/8801144/corvus-pharmaceuticals-crvs-gains-momentum-with-buy-rating-from-goldman-sachs